NEW YORK and MELBOURNE, Australia, Aug. 19, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced it will report financial results for the fourth quarter and full year ended June 30, 2016 and provide a corporate update beginning at 7:00 pm Eastern Time on Wednesday, August 24, 2016 and 9:00 am Australian Eastern Standard Time on Thursday, August 25 2016.
To access the call, dial 1 855 881 1339 (toll-free US), 1 800 558 698 (toll-free Australia) or +61 2 9007 3187 (outside of the US and Australia).
The conference identification code is 262443.
The live webcast can be accessed via: http://webcasting.boardroom.media/broadcast/578ebfb7147cda9d5dbf5728
The conference call will be accompanied by a slide presentation. Please log in approximately 15 minutes prior to the scheduled start time.
The archived webcast will be available in the Events and Presentations section of the Investor page on the Company’s website – www.mesoblast.com
Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.
For further information, please contact: Julie Meldrum Global Head, Corporate Communications Mesoblast Limited T: +61 3 9639 6036 E: email@example.com Schond Greenway VP, Investor Relations Mesoblast Limited T: +1 212 993 7993 E: Schond.Greenway@mesoblast.com